Accelerate Diagnostics INC (AXDX) Holder Miura Global Management LLC Has Cut Holding by $5.28 Million

February 21, 2018 - By Louis Casey

Investors sentiment decreased to 1.63 in Q3 2017. Its down 1.37, from 3 in 2017Q2. It fall, as 15 investors sold AXDX shares while 20 reduced holdings. 19 funds opened positions while 38 raised stakes. 21.32 million shares or 11.33% more from 19.15 million shares in 2017Q2 were reported. Fmr Ltd holds 431,699 shares or 0% of its portfolio. Utd Cap Advisers holds 0% or 13,296 shares in its portfolio. Artemis Investment Management Ltd Liability Partnership accumulated 0.05% or 100,111 shares. Prelude Cap Mngmt Limited Liability Corp holds 6,321 shares. State Common Retirement Fund owns 27,900 shares. Geode Management Ltd Liability Corp invested 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Kornitzer Ks has invested 0.21% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Legal General Grp Incorporated Public Ltd Liability Corporation invested 0% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). Price T Rowe Assoc Md stated it has 0% in Accelerate Diagnostics, Inc. (NASDAQ:AXDX). 39,641 were accumulated by Gilder Gagnon Howe & Lc. D E Shaw reported 31,841 shares or 0% of all its holdings. 12,193 are owned by Voya. Swiss Natl Bank stated it has 55,900 shares or 0% of all its holdings. Pnc Fincl Serv Gru Inc, Pennsylvania-based fund reported 3,200 shares. Art Advsrs Limited Liability reported 0.01% of its portfolio in Accelerate Diagnostics, Inc. (NASDAQ:AXDX).

Since October 12, 2017, it had 5 insider buys, and 0 insider sales for $9.01 million activity.

Pasco Alfaro / Richard Tumure decreased its stake in Accelerate Diagnostics Inc (AXDX) by 20% based on its latest 2017Q3 regulatory filing with the SEC. Miura Global Management Llc sold 240,000 shares as the company’s stock rose 20.30% with the market. The hedge fund run by Pasco Alfaro / Richard Tumure held 960,000 shares of the capital goods company at the end of 2017Q3, valued at $21.55M, down from 1.20M at the end of the previous reported quarter. Miura Global Management Llc who had been investing in Accelerate Diagnostics Inc for a number of months, seems to be less bullish one the $1.43 billion market cap company. The stock increased 4.28% or $1.05 during the last trading session, reaching $25.6. About 137,423 shares traded. Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has risen 147.12% since February 21, 2017 and is uptrending. It has outperformed by 130.42% the S&P500.

Miura Global Management Llc, which manages about $2.90B and $383.40 million US Long portfolio, upped its stake in Visa Inc (NYSE:V) by 80,000 shares to 380,000 shares, valued at $39.99M in 2017Q3, according to the filing.

Analysts await Accelerate Diagnostics, Inc. (NASDAQ:AXDX) to report earnings on May, 4. They expect $-0.33 EPS, down 22.22 % or $0.06 from last year’s $-0.27 per share. After $-0.27 actual EPS reported by Accelerate Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 22.22 % negative EPS growth.

More notable recent Accelerate Diagnostics, Inc. (NASDAQ:AXDX) news were published by: Seekingalpha.com which released: “Accelerate Diagnostics’ (AXDX) CEO Lawrence Mehren on Q4 2017 Results …” on February 16, 2018, also Prnewswire.com with their article: “Technical Perspectives on Medical Research Stocks — Accelerate Diagnostics …” published on January 29, 2018, Globenewswire.com published: “Accelerate Diagnostics to Host Q4 and Full-Year 2017 Earnings Call on February …” on February 08, 2018. More interesting news about Accelerate Diagnostics, Inc. (NASDAQ:AXDX) were released by: Globenewswire.com and their article: “Accelerate Diagnostics to Present at the 36th Annual JP Morgan Healthcare …” published on January 04, 2018 as well as Globenewswire.com‘s news article titled: “Accelerate Diagnostics achieves CE-IVD milestone for severe bacterial …” with publication date: January 10, 2018.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Ratings Coverage

Among 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Accelerate Diagnostics had 9 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) has “Outperform” rating given on Friday, January 8 by William Blair. The firm has “Neutral” rating given on Tuesday, August 25 by BTIG Research. The company was maintained on Sunday, September 17 by Piper Jaffray. JP Morgan maintained the shares of AXDX in report on Tuesday, August 9 with “Overweight” rating. The stock has “Overweight” rating by Piper Jaffray on Wednesday, December 16. The firm earned “Buy” rating on Thursday, August 3 by Piper Jaffray. BTIG Research downgraded the stock to “Neutral” rating in Wednesday, December 13 report. JP Morgan initiated it with “Overweight” rating and $17 target in Thursday, March 24 report. The stock has “Buy” rating by BTIG Research on Wednesday, July 12.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: